ZA912580B - Thiophene sulfonamides useful as carbonic anhydrase inhibitors - Google Patents

Thiophene sulfonamides useful as carbonic anhydrase inhibitors

Info

Publication number
ZA912580B
ZA912580B ZA912580A ZA912580A ZA912580B ZA 912580 B ZA912580 B ZA 912580B ZA 912580 A ZA912580 A ZA 912580A ZA 912580 A ZA912580 A ZA 912580A ZA 912580 B ZA912580 B ZA 912580B
Authority
ZA
South Africa
Prior art keywords
carbonic anhydrase
anhydrase inhibitors
sulfonamides useful
thiophene sulfonamides
useful
Prior art date
Application number
ZA912580A
Other languages
English (en)
Inventor
Thomas R Dean
R Dean Thomas
Jesse A May
A May Jesse
Hwang-Hsing Chen
Chen Hwang-Hsing
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of ZA912580B publication Critical patent/ZA912580B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA912580A 1990-04-09 1991-04-08 Thiophene sulfonamides useful as carbonic anhydrase inhibitors ZA912580B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50673090A 1990-04-09 1990-04-09
US07/618,765 US5153192A (en) 1990-04-09 1990-11-27 Thiophene sulfonamides useful as carbonic anhydrase inhibitors

Publications (1)

Publication Number Publication Date
ZA912580B true ZA912580B (en) 1992-01-29

Family

ID=27055558

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA912580A ZA912580B (en) 1990-04-09 1991-04-08 Thiophene sulfonamides useful as carbonic anhydrase inhibitors

Country Status (20)

Country Link
US (2) US5153192A (ko)
EP (1) EP0527801B1 (ko)
JP (1) JP2562394B2 (ko)
KR (1) KR100196414B1 (ko)
AT (1) ATE221527T1 (ko)
AU (1) AU655924B2 (ko)
BR (1) BR9106330A (ko)
CA (1) CA2080223C (ko)
DE (3) DE10299054I1 (ko)
DK (1) DK0527801T3 (ko)
ES (1) ES2180530T3 (ko)
FI (2) FI924553A0 (ko)
HK (1) HK1014186A1 (ko)
IL (1) IL97800A (ko)
LU (2) LU90935I2 (ko)
NL (2) NL300098I2 (ko)
NO (1) NO923948L (ko)
NZ (1) NZ237754A (ko)
WO (1) WO1991015486A1 (ko)
ZA (1) ZA912580B (ko)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585377A (en) * 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
FR2662439B1 (fr) * 1990-05-23 1993-11-19 Rhone Poulenc Chimie Reactif et procede de perfluoroalkylation de substrats nucleophiles par les perfluoroalcanesulfinates de sodium en milieu oxydant.
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
ES2118941T3 (es) * 1992-02-21 1998-10-01 Alcon Lab Inc Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.
US5308842A (en) * 1992-09-09 1994-05-03 Merck & Co., Inc. Tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds
US5276025A (en) * 1992-09-09 1994-01-04 Merck & Co., Inc. Heterobicyclic sulfonamides
WO1994006411A1 (en) * 1992-09-17 1994-03-31 Alcon Laboratories, Inc. Topical carbonic anhydrase inhibitor composition
US5344929A (en) * 1993-02-18 1994-09-06 Alcon Laboratories, Inc. Preparation of carbonic anhydrase inhibitors
US5538966A (en) * 1994-01-21 1996-07-23 Alcon Laboratories, Inc. Carbonic anhydrase inhibitors
AU1684895A (en) * 1994-01-21 1995-08-08 Alcon Laboratories, Inc. Thienothiazine sulfonamide derivatives process and intermediates for their preparation and their use as carbonic anhydrase inhibitors
US5646142A (en) * 1994-07-08 1997-07-08 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5464831A (en) * 1994-09-09 1995-11-07 Alcon Laboratories, Inc. Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US5510347A (en) * 1994-09-09 1996-04-23 Alcon Laboratories, Inc. Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US5470973A (en) * 1994-10-03 1995-11-28 Alcon Laboratories, Inc. Synthesis of sulfonamide intermediates
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
AU2998995A (en) * 1995-07-12 1997-02-10 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
ATE239468T1 (de) * 1996-02-26 2003-05-15 Advanced Res & Tech Inst Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
US5900427A (en) * 1996-05-03 1999-05-04 Wisconsin Alumni Research Foundation N-heteroarenesulfonyl-protected amino acid reagents for peptide synthesis
AUPO227896A0 (en) * 1996-09-13 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Novel compounds and their preparation
CN1178661C (zh) 1997-12-23 2004-12-08 阿尔康制药厂 布林佐拉米预防视野缺损的用途
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
CA2323749A1 (en) * 1998-03-06 1999-09-10 William E. Sponsel Composition and method for treating macular disorders
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6960579B1 (en) * 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US6548535B2 (en) * 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
ATE409491T1 (de) 2000-01-18 2008-10-15 Merck & Co Inc Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
EP1268493B1 (en) * 2000-03-31 2006-02-15 Purdue Research Foundation Phosphoramidate prodrugs
CA2428799A1 (en) * 2000-11-16 2002-05-23 Alcon Manufacturing, Ltd. Combination therapy for lowering and controlling intraocular pressure
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
WO2003077845A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. Compositions and methods for treating glaucoma and ocular hypertension
CA2487977A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
AU2003239972B2 (en) * 2002-06-14 2008-02-28 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AU2003245565B2 (en) * 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
CA2488752A1 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
CA2488884A1 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
AU2003258433A1 (en) * 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
CA2502914A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
KR100503618B1 (ko) * 2002-11-07 2005-07-26 안헌상 케이크용 장식용품
US20040216749A1 (en) * 2003-01-23 2004-11-04 Hosheng Tu Vasomodulation during glaucoma surgery
AU2004226479A1 (en) * 2003-03-27 2004-10-14 Evotec Oai Ophthalmic compositions for treating ocular hypertension
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
KR100537781B1 (ko) * 2004-06-02 2005-12-20 안헌상 케이크 장식용품의 제조방법 및 그 물품
PL1905452T3 (pl) 2005-07-12 2013-11-29 Kowa Co Środek do zapobiegania lub leczenia jaskry
JP4831668B2 (ja) * 2006-02-16 2011-12-07 独立行政法人産業技術総合研究所 新規なチアジノインドール化合物およびその製造方法
LT5504B (lt) 2006-08-02 2008-06-25 Biotechnologijos Institutas Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti
JP5301465B2 (ja) 2007-01-25 2013-09-25 バーバ・ファーマシューティカルズ・リミテッド インスリン抵抗性改善薬および治療方法
WO2008120099A1 (en) * 2007-03-30 2008-10-09 Pfizer Inc. Thieno [3, 2-e] [1, 2] thiazine derivative as inhibitor of carbonic anhydrase
EP1985618A1 (en) * 2007-04-27 2008-10-29 Duke Chem, S. A. Process for the preparation of brinzolamide and intermediates thereof
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
ITMI20081084A1 (it) * 2008-06-16 2009-12-17 Phf Sa Processo per la preparazione di brinzolamide
US8332007B2 (en) * 2009-01-12 2012-12-11 The Board Of Trustees Of The University Of Illinois Quantitative three-dimensional mapping of oxygen tension
EP2414343A1 (en) * 2009-03-13 2012-02-08 Azad Pharmaceutical Ingredients AG Process for preparing brinzolamide
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2348026A1 (en) 2009-12-22 2011-07-27 Duke Chem, S. A. Process for the preparation of brinzolamide and intermediates thereof
EP2394637A1 (en) 2010-05-21 2011-12-14 Zaklady Farmaceutyczne Polpharma SA Process for obtaining sterile brinzolamide suspensions
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
WO2012053011A2 (en) 2010-10-18 2012-04-26 Usv Limited Ophthalmic compositions comprising brinzolamide
EP2755549A1 (en) 2011-09-13 2014-07-23 Dose Medical Corporation Intraocular physiological sensor
JP5836851B2 (ja) * 2012-03-12 2015-12-24 株式会社トクヤマ ブリンゾラミドの製造方法
EP2638909A1 (en) 2012-03-15 2013-09-18 Azad Pharmaceutical Ingredients AG Process for preparing sterile Brinzolamide
JP5881514B2 (ja) * 2012-04-09 2016-03-09 株式会社トクヤマ アミン誘導体の製造方法
JP5914246B2 (ja) * 2012-08-10 2016-05-11 株式会社トクヤマ ブリンゾラミドの精製方法
CN102936236A (zh) * 2012-11-13 2013-02-20 江苏吉贝尔药业有限公司 一种布林佐胺中间体(3-乙酰基-5-氯-2-(苄基巯基)噻酚)的制备方法
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
CA2924562A1 (en) 2013-10-17 2015-04-23 Sentiss Pharma Private Limited Preservative-free ophthalmic pharmaceutical formulation
US9820991B2 (en) 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
WO2015110993A1 (en) 2014-01-24 2015-07-30 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
US10463674B2 (en) 2013-11-08 2019-11-05 Sentiss Pharma Private Limited Process for manufacturing sterile ophthalmic pharmaceutical suspensions
WO2016063184A1 (en) 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Ophthalmic solution
WO2017099207A1 (ja) * 2015-12-10 2017-06-15 千寿製薬株式会社 眼科用医薬製品
CA3043938A1 (en) 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
WO2019207380A1 (en) 2018-04-25 2019-10-31 Shilpa Medicare Limited Ophthalmic compositions of brinzolamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA661731A (en) * 1963-04-23 Siedel Walter Substituted thiophene-3,5-disulfonamides and a process for preparing them
DE1096916B (de) * 1957-12-17 1961-01-12 Hoechst Ag Verfahren zur Herstellung von Thiophen-3, 5-disulfonamiden
GB1516024A (en) * 1977-04-20 1978-06-28 Pfizer Ltd Thiophene-2,5-disulphonamides
US4746745A (en) * 1980-07-09 1988-05-24 Maren Thomas H 1,3,4-thiadiazoline-5-sulfonamides
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4731368A (en) * 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation
US4847289A (en) * 1987-06-08 1989-07-11 Merck & Co., Inc. Thiophene sulfonamide antiglaucoma agents
US5093332A (en) * 1990-10-01 1992-03-03 Merck & Co., Inc. Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents

Also Published As

Publication number Publication date
US5153192A (en) 1992-10-06
FI963424A0 (fi) 1996-09-02
JP2562394B2 (ja) 1996-12-11
CA2080223C (en) 2000-11-07
NL300098I1 (nl) 2002-11-01
NO923948L (no) 1992-12-08
FI924553A (fi) 1992-10-08
WO1991015486A1 (en) 1991-10-17
NO923948D0 (no) 1992-10-09
HK1014186A1 (en) 1999-09-24
IL97800A0 (en) 1992-06-21
IL97800A (en) 1997-08-14
DE69133080T2 (de) 2003-03-27
BR9106330A (pt) 1993-04-20
EP0527801B1 (en) 2002-07-31
AU7746791A (en) 1991-10-30
AU655924B2 (en) 1995-01-19
EP0527801A4 (en) 1993-03-10
EP0527801A1 (en) 1993-02-24
US5240923A (en) 1993-08-31
JPH05508832A (ja) 1993-12-09
DK0527801T3 (da) 2002-11-25
ATE221527T1 (de) 2002-08-15
FI963424A (fi) 1996-09-02
NL300389I1 (nl) 2009-07-01
LU91555I2 (fr) 2009-06-22
KR100196414B1 (ko) 1999-06-15
DE69133080D1 (de) 2002-09-05
KR930700490A (ko) 1993-03-15
NZ237754A (en) 1992-08-26
LU90935I2 (en) 2002-09-05
FI924553A0 (fi) 1992-10-08
DE10299054I1 (de) 2006-06-08
DE122009000026I1 (de) 2010-01-28
ES2180530T3 (es) 2003-02-16
CA2080223A1 (en) 1991-10-10
NL300098I2 (nl) 2003-01-06

Similar Documents

Publication Publication Date Title
HK1014186A1 (en) Thiophene sulfonamides useful as carbonic anhydrase inhibitors
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
HUT53521A (en) Process for producing pharmaceutical compositions comprising morphine
PH21102A (en) Improvements in or relating to benzothiophene derivatives as antiastmatic agents
HU9303749D0 (en) 2,4-substituted 5-(n-substituted-sulfamoyl)-benzoyl-guanidines, process for producing them, their use as medicine or diagnosticum and pharmaceutical compositions containing them
ES8704498A1 (es) Un procedimiento para la preparacion de una sulfamida aromatica.
HUP9902054A3 (en) Use of carbonic anhydrase inhibitors for the preparation of ophthalmic pharmaceutical compositions treating macular edema
IL106521A0 (en) Pharmaceutical composition for the treatment or prevention of elevated intraocular pressure
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
EP0129478A3 (en) 2-sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure
ATE400552T1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)- derivate und sie enthaltende zusammensetzungen
UA42722C2 (uk) Сульфіди, сульфоксиди або сульфони, або їх фармацевтично прийнятні солі і фармацевтична композиція, що їх містить
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
DK429788A (da) Thieno(2,3-beta)thiophen-2-sulfonamid og farmaceutisk praeparat indeholdende en saadan forbindelse
NZ214201A (en) Crystalline polymorph of a benzothiazine dioxide (piroxicam) salt, and pharmaceutical compositions
HUT51638A (en) Process for producing phosphonooxyalkyl derivatives of mitomycin c, the appropriate sulfur analogs and pharmaceutical compositions comprising such compounds
IL109235A0 (en) Pharmaceutical compositions containing ureido derivatives for the treatment of lentivirus-induced diseases
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
AU8744691A (en) N-((2-thenoylmercapto-3-methyl)-butanoyl)-homocysteine thiolactone, a process for the preparation thereof and pharmaceutical compositions containing it
IL106961A0 (en) Pharmaceutical compositions for treatment of the eyes
GR920100423A (el) Ανταγωνιστές 5-ΗΤ4 κινολιζιδινυλ εστέρος.
ITMI931174A0 (it) Composizioni farmaceutiche per la cura della talassemia
ZA893275B (en) Pharmaceutical composition for the treatment of migraine and the like
EP0480458A3 (en) Process for the preparation of pharmaceutical compositions containing viminol useful in the treatment of drug dependences